- Home
- SLM vs DNTH Comparison
SLM vs DNTH Comparison
Compare SLM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLM | DNTH |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | 1788 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SLM | DNTH |
|---|---|---|
| Price | $25.33 | $93.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $31.09 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.1M | 1.3M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $3.35 | N/A |
| Revenue Next Year | $5.68 | $29.48 |
| P/E Ratio | $6.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.77 | $18.08 |
| 52 Week High | $33.59 | $98.70 |
Technical Indicators
Market Signals| Indicator | SLM | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 68.86 | 58.81 |
| Support Level | $25.43 | $79.27 |
| Resistance Level | $28.38 | $96.50 |
| Average True Range (ATR) | 0.84 | 5.26 |
| MACD | 0.31 | 1.20 |
| Stochastic Oscillator | 87.68 | 79.76 |
Price Performance
Historical ComparisonAbout SLM SLM Corporation
SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.